Short communicationImmunohistochemical study on the distribution of insulin-like growth factor I (IGF-I) receptor in the central nervous system of SOD1G93A mutant transgenic mice
Section snippets
Acknowledgements
This study was supported by Seoul National University Hospital Research Fund (03-2003-002). This study was supported in part by year 2003 BK21 project for Medicine, Dentistry and Pharmacy.
References (28)
- et al.
Alterations in spinal cord excitatory amino acid receptors in amyotrophic lateral sclerosis patients
Brain Res.
(1992) - et al.
Neurite promoting activity of insulin, insulin-like growth factor I and nerve growth factor on spinal motoneurons is astrocyte dependent
Brain Res. Dev. Brain Res.
(1993) - et al.
Immunocytochemical study on the distribution of nitrotyrosine in the brain of the transgenic mice expressing a human Cu/Zn SOD mutation
Brain Res.
(2000) - et al.
Immunohistochemical study on the distribution of homocysteine in the central nervous system of transgenic mice expressing a human Cu/Zn SOD mutation
Brain Res.
(2003) - et al.
Distribution and levels of insulin-like growth factor (IGF-I and IGF-II) and insulin receptor binding sites in the spinal cords of amyotrophic lateral sclerosis (ALS) patients
Brain Res. Mol. Brain Res.
(1996) - et al.
The insulin-like growth factor signaling system and ALS neurotrophic factor treatment strategies
J. Neurol. Sci.
(1995) - et al.
Expression of insulin-like growth factor-I and related peptides during motoneuron regeneration
Exp. Neurol.
(1994) - et al.
Cognitive impairment in amyotrophic lateral sclerosis: evidence from neuropsychological investigation and event-related potentials
Brain Res. Cogn. Brain Res.
(2002) - et al.
Insulin-like growth factor-I: potential for treatment of motor neuronal disorders
Exp. Neurol.
(1993) - et al.
Visual and auditory event-related potentials in sporadic amyotrophic lateral sclerosis
Clin. Neurophysiol.
(2002)
Immunohistochemical study on the distribution of Bcl-2 and Bax in the central nervous system of the transgenic mice expressing a human Cu/Zn SOD mutation
Brain Res.
Focal reductions of cerebral blood flow in amyotrophic lateral sclerosis: a [99mTc]-d,l-HMPAO SPECT study
J. Neurol. Sci.
Free insulin-like growth factor (IGF)-I and IGF binding proteins 2, 5, and 6 in spinal motor neurons in amyotrophic lateral sclerosis
Lancet
Growth factor receptors in amyotrophic lateral sclerosis
Mol. Neurobiol.
Cited by (24)
Molecular classification of amyotrophic lateral sclerosis by unsupervised clustering of gene expression in motor cortex
2015, Neurobiology of DiseaseCitation Excerpt :Differential expression of Angiotensin II and its type-1 receptor may be linked to the altered levels of Angiotensin II found in liquor of ALS patients (Kawajiri et al., 2009), whereas that of Leukemia inhibitory factor (LIF) and its receptor are consistent with a study proposing LIF as a modifier gene in ALS (Giess et al., 2000). The up regulation of IGF1 receptor is in agreement with previous studies (Chung et al., 2003; Wilczak et al., 2003), whereas that of purinergic receptor P2Y2 supports the role for P2 receptor signaling in ALS (D'Ambrosi et al., 2009). A number of genes encoding proteins regulation ion homeostasis were deregulated in motor cortex of SALS patients (Fig. 9).
Insulin-Like Growth Factors in the Peripheral Nervous System
2012, Endocrinology and Metabolism Clinics of North AmericaCitation Excerpt :In the wobbler mouse, a model of lower MN degeneration, subcutaneous IGF-I treatment improves motor function.111 Examination of an ALS mouse model indicates that mutant SOD1 expression in Schwann cells induces diminished IGF-I levels in nerves that enhance disease progression,112 and that increased IGF-I expression is observed in astrocytes in the spinal cord.113 Subcutaneous administration of IGF-I in ALS mice, however, demonstrates no significant impact on survival.104
Motor neuron trophic factors: Therapeutic use in ALS?
2011, Brain Research ReviewsCitation Excerpt :IGF-1 receptors are expressed not only by MNs but also by oligodendrocytes, Schwann cells, astrocytes, smooth and skeletal muscle cells and endothelial cells, indicating a plethora of potential cellular non-autonomous mechanisms by which IGF-1 could regulate MN disease. Evidence for such signaling is provided by the finding that although the serum or spinal cord levels of IGF-1 are normal in ALS patients (Braunstein and Reviczky, 1987; Adem et al., 1994), increased astrocytic IGF-1 receptor expression is observed in the spinal cord of human ALS patients and fALS mice (Adem et al., 1994; Chung et al., 2003; Dagvajantsan et al., 2008). When administered at symptom onset, exogenous IGF-1 attenuates the loss of muscle weight and decline of behavioural performance in wobbler mutant mice (Hantaï et al., 1995).
Exercise modulates insulin-like growth factor 1-dependent and -independent effects on adult hippocampal neurogenesis and behaviour
2010, Molecular and Cellular NeuroscienceInteractions of estradiol and insulin-like growth factor-I signalling in the nervous system: New advances
2010, Progress in Brain ResearchCitation Excerpt :In addition to the neuroprotective effects of peripheral IGF-I, local IGF-I produced in the nervous system may also play a role in neuroprotection. Brain injury induces the synthesis of IGF-I and estradiol by reactive astrocytes (Garcia-Estrada et al., 1992; Garcia-Segura, 2008; Hwang et al., 2004; Saldanha et al., 2009) and up-regulates ERs, IGF-I receptors, and IGF-binding proteins in reactive glia (Beilharz et al., 1998; Blurton-Jones and Tuszynski, 2001; Chung et al., 2003; Garcia-Ovejero et al., 2002). Therefore, estradiol and IGF-I released by reactive glia may act directly on these cells or on neighbouring neurons, regulating reactive gliosis, neuronal survival and the reorganization of neural tissue after injury.